28 results about "Hepatitis virus c" patented technology

The present invention relates to a composition for detecting hepatitis C viruses HCV 4, HCV 1b, HCV 1, HCV 2 and HCV 3 and differentiating same, and the use thereof.

The present invention relates to a pharmaceutical composition and the like containing a stimulant for PWAR5 expression as an active ingredient for preventing or treating infectious diseases due to hepatitis C virus, the present invention allowing the PWAR5 level to be sustained at a high level inside the cell to effectively inhibit proliferation of HCV.

Described herein is a singleplex RT-LAMP-based tests using modified primer sets. Contrived whole blood samples containing HIV-1 or HCV virions were diluted in equal parts water and loaded directly into optimized RT-LAMP master mixes. To mitigate cold-chain storage dependence, RT-LAMP reactions were performed using a lyophilized master mix. The reactions were heated for, for example 30 minutes using a hand-held, battery-powered heating device for simultaneous virion lysis and amplification.

This disclosure provides a recombinant hepatitis C virus glycoprotein comprising heterodimers of E1 and E2 glycoproteins having at least 60% homology with SEQ ID No. 1, engineered furin protease cleavage sites, and hydrophilic amino acid linkers, wherein the E1 and E2 glycoproteins partially or completely lack their respective transmembrane domains. This document further provides nucleic acids encoding the recombinant hepatitis C virus glycoprotein, nanoparticle conjugates comprising the recombinant hepatitis C virus glycoprotein, and compositions comprising the recombinant hepatitis C virus glycoprotein, the nucleic acid, or the nanoparticle conjugate. Applications of the recombinant hepatitis C virus glycoprotein or compositions comprising the glycoprotein are also envisioned.

The invention relates to the technical field of medical examination, in particular to a rapid extraction-free hepatitis C virus detection kit and method. According to the invention, the material carrier is used for providing carrier support for reagent freeze-drying, and during use, the remelting buffer solution is used for remelting, so that the use effect before freeze-drying is achieved. The kit provided by the invention is used as a freeze-drying reagent, and solves the problem of cold-chain transportation of nucleic acid detection kits. The product simulates storage under different temperature conditions, detection results show that the product changes within 15 months, the storage period exceeds that of a control kit, and a new direction is laid for development and exploration of a later nucleic acid detection kit (pcr method). The kit disclosed by the invention lays a foundation for market occupation and long-term development by utilizing storage stability and transportation stability of the kit.

The invention discloses a digital PCR nucleic acid detection kit, and relates to the technical field of in vitro diagnosis detection, the kit comprises primers, probes, a reaction liquid and a quality control liquid, the kit is used for simultaneously detecting hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus and hepatitis E virus, the reaction liquid comprises Master Mix and sterile enzyme-free water, and the quality control liquid is used for simultaneously detecting the hepatitis A virus, the hepatitis B virus, the hepatitis C virus, the hepatitis D virus and the hepatitis E virus. The quality control liquid comprises a negative quality control product and a positive quality control product. Through cooperation of sample collection, sample treatment, digital PCR reaction system preparation, digital PCR amplification and result analysis, nucleic acid detection based on the PCR technology shortens the window period by 50-70% through direct detection of virus genetic materials, becomes a key means for early diagnosis, and adopts the technical principle of digital PCR to realize rapid detection of the virus genetic materials. Compared with a traditional fluorescent quantitative PCR and immunological detection method and a qPCR method, the detection sensitivity is improved by 10-100 times, and absolute quantification can be achieved.

The invention relates to the technical field of biomedicine, and provides a new target, a new small nucleic acid drug and application of the new small nucleic acid drug in preparation of drugs for prevention or treatment for resisting infection of three viruses of Zika virus (ZIKV), dengue virus (DENV) and hepatitis C virus (HCV). According to the invention, the specific nucleotide sequences of the target lipid droplet coating protein (Perilipin), which are shown as SEQ ID NO.1 to SEQ ID NO.3, are obtained through screening. Experiments discover that Perilipin plays an important role in flavivirus infected target cells, expression and replication of the three virus proteins and genome RNA in the target cells can be effectively blocked by down-regulating expression of Perilipin, and therefore it is proved that Perilipin can serve as a new target spot for resisting infection of the three flaviviruses, and the application of Perilipin in resisting flavivirus infection is proven to be a new target spot for resisting infection of the three flaviviruses. Specific small nucleic acid can be used as an antiviral drug for the three flaviviruses.

The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and / or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1 / E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

The invention discloses a sample liquid experiment table for hepatitis C virus detection, and relates to the technical field of virus detection, the sample liquid experiment table comprises a shell, a lifting mechanism and a cleaning mechanism; an opening is formed in the upper end of the shell, and a partition plate is horizontally fixed in an inner cavity; the mounting end of the driving assembly is fixed to the inner bottom wall of the shell, and the output end of the driving assembly penetrates through the partition plate. The pressing rod is fixed on the driving assembly; the placement plate and the detection mechanism can form a sealed space, and the bottom wall of the placement plate is fixedly connected with the output end of the driving assembly; the mounting end of the transmission assembly is fixed to the inner side wall of the shell, and the transmission end of the transmission assembly penetrates through the partition plate to be fixed to the elastic telescopic mechanism. The push plate surface is fixed at the other end of the transmission assembly; one end of the pressing plate is fixed to the transmission assembly, and the other end abuts against the pressing rod. In the hepatitis C detection process, it can be guaranteed that direct contact between an operator and a test tube can be reduced as much as possible in the detection process or after detection is completed, and some potential risks of the operator are avoided.

Described herein are CRISPR / Cas-based methods, systems, compositions, and kits relating to the detection of one or more target polynucleotides that do not require the presence of a PAM sequence. In certain aspects, methods, systems, compositions, and kits utilize Cas12a, customized guide RNA, and an isothermal amplification buffer for polynucleotide detection. In certain aspects, methods, systems, compositions, and kits as described herein can detect SARSCoV-2, and variants thereof; hepatitis C virus (HCV), and variants thereof, human immunodeficiency virus (HIV) and variants thereof, among others. In certain aspects, methods, systems, compositions, and kits can be employed in a point-of-care setting without the use of a thermocycler.

The present application relates to a circRNA vaccine for anti-infectious hematopoietic necrosis virus, the circRNA vaccine is a covalently closed circular structure, comprising an internal ribosome entry site, a G protein sequence of the infectious hematopoietic necrosis virus, and a Kozak sequence located between the internal ribosome entry site and the G protein sequence of the infectious hematopoietic necrosis virus;The circRNA vaccine comprises a cyclization connection sequence formed by a fish tRNA Leu I type intron self-splicing;The internal ribosome entry site is one or more of the following: coxsackievirus 3 IRES, infectious pancreatic necrosis virus IRES, encephalomyocarditis virus IRES, Ythdc2 IRES, and hepatitis C virus IRES;The amino acid sequence of the G protein of the infectious hematopoietic necrosis virus has at least 90% sequence identity with the amino acid sequence encoded by SEQ ID NO. 1.

The present invention relates to monoclonal antibodies to the HCV core lipid binding domain. The present invention provides monoclonal antibodies for detecting Hepatitis C Virus (HCV) antigens. The antibodies specifically immunoreact with at least one epitope of the lipid binding domain of amino acid residues 134-171 of the HCV core antigen. Further provided are immunoassay methods for detecting HCV infection using the antibodies, kits comprising the antibodies, and compositions.

The application discloses a postpartum hepatitis C referral management system based on a mobile terminal and relates to the medical management field.The system comprises a medical communication module, a data entry module and an index preset module.The medical communication module is used for integrating the communication permission of the mobile terminal and providing a plurality of communication channels.The data entry module is used for periodically collecting and entering the liver function indexes, the hepatitis C virus load data and the emotional evaluation scores of puerpera through the medical communication module.The index preset module is used for presetting the benchmark feeding indexes of future periods according to a newborn growth model.The risk prediction module is used for collecting the data of the current period data entry module and the preset feeding indexes of the next period based on the risk prediction model.The risk coefficient of breastfeeding behavior is dynamically predicted by using the risk prediction model, the potential risks under different feeding schemes are quantitatively evaluated, the high-risk puerpera are early identified, the disease deterioration or the risk of mother-to-child transmission caused by delayed intervention is reduced, the human error is reduced, and the accuracy and response speed of postpartum hepatitis C management are improved.

The utility model relates to a hepatitis C detection kit. The sampling part and the detection part are located in the box body, the sampling part comprises a capillary tube with oblique notches at the two ends, one end of the capillary tube can collect a detection sample, the other end of the capillary tube is inserted into a detection chamber with a vacuum cavity inside after collection is completed, and the detection sample is detected through detection test paper located in the detection chamber. According to the utility model, through the integrated design of collection and detection and the combination of the collection part and the detection part in the box body, the technical problem that the risk of leakage of samples carrying hepatitis C viruses is increased due to multiple steps and independent operation in the traditional hepatitis C detection process is solved.

The invention discloses a real-time fluorescent quantitative PCR (Polymerase Chain Reaction) kit for quantitatively detecting HCV (Hepatitis C Virus) load through a single tube, and belongs to the technical field of molecular biological detection. The kit comprises a pair of primer and probe combination, and the primer and probe combination comprises a primer pair and a probe for detecting a target gene and a probe for detecting an internal standard. The kit can be used for detecting clinical common types of HCV 1-6, the coverage types are comprehensive, the virus load of 10 IU / mL can be stably detected, the detection sensitivity is high, the repeatability is good, an additional quantitative reference substance is not needed to construct a calibration curve, the operation is simplified, the utilization rate of the reagent is improved, and invalid results and repeated detection caused by failed construction of the calibration curve are avoided.

The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.

This disclosure provides oligomers, compositions, and kits for detecting and quantifying Hepatitis C virus (HCV), including different genotypes and variants thereof, and related methods and uses. In some embodiments, oligomers target the 5′ untranslated region of HCV and are configured to provide substantially equivalent quantification of different genotypes and variants of HCV.

The present invention provides a kit for ultrasensitive extraction of hepatitis C virus RNA by magnetic bead method and its extraction method. The kit includes an extraction reagent group for ultrasensitive extraction of hepatitis C virus RNA; the extraction reagent group consists of magnetic bead lysate, washing solution I, washing solution II and eluent; the magnetic bead lysate consists of sodium citrate, sodium lauroyl sarcosinate, sodium acetate, sodium metabisulfite, guanidine thiocyanate, ethanol and magnetic bead suspension; washing solution I consists of guanidine thiocyanate, sodium chloride, Tween-20, sodium acetate and ethanol aqueous solution. The present invention obtains the optimal ratio and extraction conditions for extracting hepatitis C virus nucleic acid by rationally compounding each raw material. While ensuring that the extracted hepatitis C virus RNA has a high detection rate, good repeatability and low error after fluorescent quantitative PCR, ultrasensitive detection of hepatitis C virus RNA is achieved. The extraction method can detect 100% of virus samples with a concentration of 10 IU / mL.

The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.

A method for preparing an immunogenic composition, which comprises treating HCV pseudoparticles with α2-3,6,8,9 neuraminidase A to generate the immunogenic composition. In addition, the immunogenic compositions are made in vaccines for eliciting an immune response to HCV in a subject.

The present invention discloses an anti-HCV core antigen monoclonal antibody, a hybridoma cell line and their applications. Specifically, a hybridoma cell line screened against the common conserved sequence of the core proteins of different genotypes of HCV, and the antibody secreted by it is used in the detection of HCV antigens, which can detect hepatitis C viruses of different genotypes, has good inclusiveness, and only two antibodies are needed to achieve the above technical effects. This can not only reduce the production cost of HCV antigen detection kits, but also reduce the production difficulty and improve the production efficiency.

The present disclosure provides an immunogenic composition comprising one or more T cell epitope polypeptides or a fusion polypeptide comprising two or more T cell epitope polypeptides.The present disclosure provides a method of inducing an immune response against Hepatitis C virus in an individual, the method comprising administering to the individual an immunogenic composition of the present disclosure.

The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleosidemodified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.

The utility model provides a kind of HCV recombination antigen purification process device, specifically relates to antigen purification field, filler in chromatography column is nickel column filler;The upper and lower sides of interlayer are respectively equipped with water inlet and water outlet;Water inlet is sequentially connected constant-current pump, pre-cooling water bucket by water inlet rubber tube;Water outlet is connected with pre-cooling water bucket by water outlet rubber tube;Protein purification complete system includes conductivity meter, electric ultraviolet light detector, PH detector;Constant-current A pump and constant-current B pump one end are connected with sample A barrel, sample B barrel respectively by import connection pipe, and constant-current A pump and constant-current B pump other end are connected with the liquid inlet of chromatography column by import connection pipe through mixer;The liquid outlet of chromatography column is connected with sample barrel by outlet connection pipe sequentially through conductivity meter, electric ultraviolet light detector, pH detector.The utility model can reduce the tedious operation in experimental process to make test process more succinct, while guaranteeing the production activity and purity of recombination antigen.

The present invention addresses the problem of providing: a compound having a hepatitis C virus (HCV) inhibition activity and can prevent and / or treat hepatitis C; and a medicine containing the compound. [Solution] The present invention provides: a compound having a structure represented by formula (I) or (IV) and having an HCV inhibition activity; and a composition containing the compound.

The present invention relates to a composition for detecting hepatitis C viruses HCV 4, HCV 1b, HCV 1, HCV 2 and HCV 3 and differentiating same, and the use thereof.